Clinical trials: Peripheral Artery Disease
Peripheral Arterial Disease
ChampioNIR® SFA Stent EFS Study
An Early Feasibility Study to Assess Safety and Efficacy of the ChampioNIR® SFA Stent in the Treatment of Patients with Femoro-Popliteal Disease
- Trial name
- NCT03775226
- Testing
- ChampioNIR® SFA Stent
- Where
- 3 sites in Israel
- Volunteers
- 22 people
- Sponsor
- Medinol Ltd.
Angioplasty, Peripheral Arterial Disease
Safety and Effectiveness Evaluation of iCover Covered Stent for the Treatment of the Aorto-iliac Occlusive Disease
The objective of this prospective, multi-center, non-randomized, single-arm observational study is to evaluate the safety and the efficacy of the iCover covered stent over a 24-month follow-up period for the treatment of de novo…
- Conditions
- Angioplasty, Peripheral Arterial Disease, Iliac Artery Disease, Covered Stent
- Trial name
- iliCo (NCT05192616)
- Testing
- Covered stent implantation
- Where
- 18 sites in Belgium, France and 2 more
- Volunteers
- 241 people
- Sponsor
- iVascular S.L.U.
Peripheral Arterial Disease
"Unifuzol®" in Patients With Peripheral Arterial Disease
The present study is a multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of the drug Unifuzol® (L-arginine) in patients with obliterating atherosclerosis of the lower extremities.
- Trial name
- NCT03861416
- Testing
- L-arginine 1.4% 500 ml
- Where
- 19 sites in Russia
- Volunteers
- 360 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Peripheral Vascular Diseases
A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)
A 12-Week Efficacy Study in participants with Peripheral Arterial Disease. the primary hypothesis is that MK-0736 7 mg administered once daily for 12 weeks will result in a decrease in lower extremity atherosclerotic plaque…
- Trial name
- NCT00679055
- Testing
- MK-0736
- Volunteers
- 14 people
- Sponsor
- Merck Sharp & Dohme LLC
Peripheral Arterial Disease
Kaitoh Atherectomy FIH
This is a prospective, multi-center and single-arm clinical study to assess the initial safety and effectiveness of the Kaitoh Atherectomy System for the treatment of de novo and/or restenotic lesion(s) in the peripheral arteries.
- Trial name
- NCT05873452
- Testing
- Kaitoh Atherectomy System
- Where
- 2 sites in New Zealand
- Volunteers
- 9 people
- Sponsor
- Terumo Medical Corporation
Peripheral Vascular Disease
Safety/Feasibility Study of HBOC-201 in Amputation at/Below Knee From Critical Lower Limb Ischemia
The purpose of this study is to assess the safety and feasibility of HBOC-201 in increasing adequate wound healing in patients with severe peripheral vascular disease who are undergoing lower limb amputation.
- Trial name
- NCT00300040
- Testing
- Hemoglobin glutamer 250 - bovine, 6% Hydroxyethylstarch
- Where
- 5 sites in South Africa, United Kingdom
- Volunteers
- 16 people
- Sponsor
- Biopure Corporation
Peripheral Vascular Disease
Endovascular Atherectomy Safety and Effectiveness Study
The purpose of this study is to evaluate the procedural safety and effectiveness of the Phoenix Atherectomy™ System for the treatment of de novo and restenotic atherosclerotic lesions located in the native peripheral arteries.
- Trial name
- EASE (NCT01541774)
- Testing
- Phoenix Atherectomy System
- Where
- 16 sites in United States, Germany
- Volunteers
- 128 people
- Sponsor
- AtheroMed, Inc
Peripheral Vascular Disease
Atrium iCAST Iliac Stent Pivotal Study
Prospective, multicenter, non-randomized, single-arm registry to evaluate the safety and effectiveness of the iCAST Covered Stent System in the treatment of patients with symptomatic claudication or rest pain and angiographic…
- Trial name
- iCARUS (NCT00593385)
- Testing
- iCAST covered stent
- Where
- 25 sites in United States, Germany
- Volunteers
- 165 people
- Sponsor
- Atrium Medical Corporation
Intermittent Claudication, Peripheral Artery Disease
Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)
The objective of the study is to establish the safety profile of Intramuscular PLX-PAD injections and to evaluate the clinical efficacy of it in IC subjects comprising of 4 treatment groups: 1.
- Trial name
- NCT01679990
- Testing
- PLX-PAD Low dose, PLX-PAD high doses
- Where
- 34 sites in United States, Germany and 2 more
- Volunteers
- 180 people
- Sponsor
- Pluristem Ltd.
Critical Limb Ischemia, Peripheral Arterial Disease
Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction
A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of Rejuveinix in Combination With Standard Interventional Therapy for Critical Limb Ischemia Patients with Rutherford Class 4, 5 and 6 Disease
- Trial name
- RESTORE (NCT03041259)
- Testing
- Rejuveinix Low Dose, Rejuveinix High Dose
- Volunteers
- 320 people
- Sponsor
- Reven Pharmaceuticals, Inc.
Peripheral Arterial Disease Below The Knee
Investigating the Safety and Clinical Performance of Seven iVascular Devices for Endovascular Intervention in the Popliteal and/or Infrapopliteal Arteries
The rationale of this study is to confirm and support the clinical safety and performance of the Oceanus 14pro, Oceanus 18 and Oceanus 35 Balloon Catheters, the Luminor 14m and Luminor 18 Drug Coated Balloons, the Angiolite BTK…
- Trial name
- POP-BTK (NCT05267548)
- Where
- 8 sites in Belgium
- Volunteers
- 143 people
- Sponsor
- iVascular S.L.U.
Critical Limb Ischemia
Evaluation of the Tissue Genesis® Icellator Cell Isolation System™ to Treat Critical Limb Ischemia
The purpose of this study is to determine the safety and effectiveness of the Tissue Genesis® Icellator Cell Isolation System™ in Critical Limb Ischemia.
- Trial name
- CLI-DI (NCT02234778)
- Testing
- TGI SVF material via intramuscular injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Tissue Genesis
Peripheral Arterial Disease, Peripheral Vascular Disease
Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia
The purpose of this study is to evaluate the safety and activity of two doses of MultiGeneAngio, a cell therapy product produced from the patient's own cells, as potential treatment for patients with chronic critical limb…
- Conditions
- Peripheral Arterial Disease, Peripheral Vascular Disease, Critical Limb Ischemia
- Trial name
- NCT00956332
- Testing
- MultiGeneAngio
- Where
- 7 sites in Israel
- Volunteers
- 28 people
- Sponsor
- MultiGene Vascular Systems Ltd.
Acute Coronary Syndromes (ACS), Recent Myocardial Infarction
The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate）and Plavix® in Healthy Participants
CG-0255 is a novel investigational prodrug of the active metabolite of Plavix®， but with different active metabolite conversion routes.
- Conditions
- Acute Coronary Syndromes (ACS), Recent Myocardial Infarction, Recent Stroke, Peripheral Arterial Disease
- Trial name
- NCT07619885
- Testing
- CG-0255 Besylate for Injection, CG-0255 Besylate Capsule, Clopidogrel
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Shanghai CureGene Pharmaceutical Co., Ltd.
Critical Limb Ischemia (CLI)
Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
A Phase III study of PLX-PAD for CLI patients with minor tissue loss who are unsuitable for revascularization has been initiated (PLX-CLI-03, PACE study).
- Trial name
- NCT03886506
- Testing
- PLX-PAD
- Where
- 2 sites in United States
- Sponsor
- Pluristem Ltd.
Peripheral Arterial Disease
Multi-center Study for Stent Graft System for Peripheral Artery
The utility of GP1101 will be evaluated relative to that of surgical bypass in the treatment of Femoral/Popliteal Arterial Symptomatic Peripheral Arterial Disease.
- Trial name
- VJH11-01 (NCT01575808)
- Testing
- GP1101
- Where
- 15 sites in Japan
- Volunteers
- 133 people
- Sponsor
- W.L.Gore & Associates
Peripheral Arterial Occlusive Disease
Retrospective Safety Survey In Patients Included In NV1FGF Clinical Trials
The objective of this study is to collect retrospectively long term safety data in patients who have participated in the previous phase I-II trials conducted with the compound.
- Trial name
- TALISMAN S (NCT01135797)
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 164 people
- Sponsor
- Sanofi
Peripheral Arterial Disease, Intermittent Claudication
Study to Evaluate the Lower Extremity Intervention With Integrated Embolic Protection Using the Vanguard IEP System
The ENTRAP Study is a prospective, multi-center, non-randomized, single-arm, study with follow-up to 30 days to determine the acute safety, acute device performance and clinical performance of the Vanguard IEP Peripheral Balloon…
- Conditions
- Peripheral Arterial Disease, Intermittent Claudication, Atherosclerosis of Femoral Artery
- Trial name
- ENTRAP (NCT03271710)
- Testing
- peripheral balloon angioplasty
- Where
- 9 sites in Belgium, Germany
- Volunteers
- 113 people
- Sponsor
- Contego Medical, Inc.
Peripheral Arterial Disease
Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease
This study is a double-blind study to evaluate the efficacy and safety of NV1FGF, a pCOR plasmid constructed by inserting the gene coding for the FGF compared to placebo in patients with severe Peripheral Arterial Occlusive…
- Trial name
- TALISMAN 201 (NCT00368797)
- Testing
- XRP0038 (NV1FGF)
- Where
- 6 sites in Belgium, France and 4 more
- Volunteers
- 125 people
- Sponsor
- Sanofi
Critical Limb-Threatening Ischemia, Critical Limb Ischemia
Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Disease in Australia
The objective of this prospective, multi-center, clinical investigation is to evaluate the MAGNITUDE BRS System for the planned treatment of narrowed infrapopliteal lesions.
- Conditions
- Critical Limb-Threatening Ischemia, Critical Limb Ischemia, Critical Lower Limb Ischemia
- Trial name
- MAGNITUDE-BTK (NCT06075940)
- Testing
- MAGNITUDE BRS
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- R3 Vascular Inc.